The EU's medicines regulator said it is investigating reports of possible "acute" kidney damage in patients taking the coronavirus drug remdesivir, made by US pharma giant Gilead.
The European Medicines Agency recommended the use of the anti-viral drug, sold under the brand name Veklury, in June after studies showed it could reduce the length of hospital stays for Covid-19 sufferers. "EMA's safety committee has started a review...
to assess reports of acute kidney injury in some patients with Covid-19 taking Veklury (remdesivir)," it said in a statement.
The regulator said it had "not been determined whether there is a causal relationship" between remdesivir and kidney problems, but that the issue "warrants further investigation." Covid-19